Finepoint Capital LP Cerevel Therapeutics Holdings, Inc. Transaction History

Finepoint Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$20.26 - $31.91 $1.43 Million - $2.26 Million	70,800 Added 14.37%	563,345 $12.3 Million
Q2 2023 Aug 11, 2023	SELL	$23.9 - $35.38 $1.12 Million - $1.66 Million	-46,900 Reduced 8.69%	492,545 $15.7 Million
Q1 2023 May 12, 2023	BUY	$22.82 - $35.32 $505,645 - $782,620	22,158 Added 4.28%	539,445 $13.2 Million
Q4 2022 Feb 13, 2023	SELL	$25.35 - $31.96 $497,214 - $626,863	-19,614 Reduced 3.65%	517,287 $16.3 Million
Q3 2022 Nov 10, 2022	BUY	$25.5 - $41.42 $13.7 Million - $22.2 Million	536,901 New	536,901 $15.2 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Finepoint Capital LP, based on Form 13F filings with the SEC.

Stay updated on Finepoint Capital LP with notifications on news.